期刊文献+

77例骨肉瘤患者预后的多因素分析 被引量:2

Multivariate analysis on prognostic factors among 77 patients with osteosarcoma
下载PDF
导出
摘要 目的:探讨影响骨肉瘤患者预后的相关因素。方法:回顾性分析2000年1月至2011年10月,77例资料完整骨肉瘤患者的临床资料,并根据是否接收化疗药物治疗且坚持4个周期以上分为规律化疗组及非规律化疗组。结果:规律化疗组患者的比例为54.55%(42/77),非规律化疗组的比例为45.45%(35/77)。所有患者生存时间为9-62个月,5年总体生存率为44.16%(34/77),平均生存时间36.71±14.80个月,中位生存时间为31个月。规律化疗组患者5年生存率(50.00%,21/42)显著高于非规律化疗组(37.14%,13/35)(Log Rank:χ2=8.27,P=0.004);COX多因素分析发现:Enneking分期、手术方式及规律化疗是影响骨肉瘤患者5年生存率的独立因素。结论:Enneking分期、手术方式及规律化疗是影响骨肉瘤患者预后的独立因素。 Objective:To investigate the prognostic factors that influence survival in patients with osteosarcma. Methods:The clinical data of 77 patients with osteosarcoma,among which the combined therapy (resection of tumor with chemotherapy) and uncombined therapy group,based on whether receiving chemotherapy drug therapy and adhering to the four cycle or above or not,between January 2000 and October 2011 were retrospectively reviewed. Results: The proportion of patients of combined therapy group was 54.55% (42/77) , and the proportion in uncombined therapy group was 45.45% (35/77). The survival time ranged from 9 to 62 months with a median survival of 31 months,with overall 5 year overall smwival rate 44.16% (34/77). The survival rate(50.00% ,21/42) in combined therapy group,was significantly higher than that in the tmeombined therapy group(37.14% , 13/35) ,P 0. 004. Multivariate analysis by COX regression model suggested Enneking stage,surgical method and combined therapy were the independent prognostic factors. Conclusion: Enneking stage, surgical method and combined therapy were the independent prognostic factors that influenee survival in patients with osteosarema.
出处 《现代肿瘤医学》 CAS 2014年第2期447-450,共4页 Journal of Modern Oncology
关键词 骨肉瘤 预后 多因素分析 osteosarcoma prognosis multivariate analysis
  • 相关文献

参考文献18

  • 1Gill J,Ahluwalia MK,Geller D. New targets and approaches in osteosarcoma[J].{H}Pharmacology & Therapeutics,2012.13.
  • 2Wong KC,Lee V,Shing MM. Surgical resection of relapse may improve postrelapse survival of patients with localizedosteosarcoma[J].{H}Clinical Orthopaedics and Related Research,2012.1007.
  • 3Longhi A,Errani C,De Paolis M. Primary bone osteoscarcoma in the pediatric age:state of the art[J].{H}Cancer Treatment Reviews,2006,(06):423-436.
  • 4Rosen G,Tan C,Sanmaneechai A. The rationale for multiple drug chemotherapy in the treatment of osteogenic sarcoma[J].{H}CANCER,1975,(3 suppl):936-945.
  • 5Rosen G,Caparros B,Huvos AG. Preoperative chemotherapy for osteogenic sarcoma:selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy[J].{H}CANCER,1982,(06):1221-1230.
  • 6Jaffe N. Osteosarcoma:review of the past,impact on the future.The American experience[J].{H}Cancer Treat Research,2010.239-262.
  • 7张清,徐万鹏,郭卫,沈靖南,陶惠民,姚阳,毕文志,吴苏稼,张伟滨,杨蕴,于秀淳,李建民,郭征,徐绍年,熊进,朱兵,韦兴,杜心如,牛晓辉.我国骨肉瘤治疗现状及改进建议—17家骨肿瘤治疗中心1998~2008年资料分析[J].中国骨肿瘤骨病,2009,8(3):129-132. 被引量:46
  • 8Enneking WF,Spanier SS,Goodman MA. A system for the surgical staging of musculoskeletal sarcoma[J].{H}Clinical Orthopaedics and Related Research,1980.106-120.
  • 9Enneking WF,Dunham W,Gebhardt MC. A system for the functional evaluation of reconstructive p rocedures after surgical treatment of tumors of the musculoskeletal system[J].{H}Clinical Orthopaedics and Related Research,1993.241-248.
  • 10Rozeman LB,Cleton-Jansen AM,Hogendoorn PC. Pathology of primary malignant bone and cartilage tumours[J].{H}International orthopaedics,2006,(06):437-444.

二级参考文献28

  • 1蒋智铭,张惠箴,陈洁晴,黄瑾,刘亮.骨肉瘤的组织学类型[J].临床与实验病理学杂志,2004,20(3):263-266. 被引量:15
  • 2Enneking W F, Spanier S S, Goodman M A. A system for the surgical staging of musculoskeletal sarcoma. Clin Orthop Relat Res, 1980(153): 106-120.
  • 3Steele G.Follow-up plans after treatment of primary colon and rectum cancer.World J Surg,1991,15(5):583-588.
  • 4Ito K,Hibi K,Ando H,et al.Usefulness of analytical CEA doubling time and hife-life time for overlooked synchronous metastases in colorectal carcinoma.JPN J Clin Oncol,2002,32(2):54-58.
  • 5PICCI P.Osteosarcoma (osteogenic sarcoma)[J].Orphanet J Rare Dis,2007,2:6.
  • 6EKE T,OJAIMI J,KITAGAWA Y,et al.Outcome of patients with osteosarcoma over 40 years of age:Is angiogenesis a marker of survival[J].Int Semin Surg Oncol,2006,3:7.
  • 7GRIMER R I,CANNON S R,TAMINIAU A M,et al.Osteosarcoma over the age of forty[J].Eur J Cancer,2003,39 (2):157-163.
  • 8CARSI B,ROCK M G.Primary osteosarcoma in adults older than 40 years[J].Clin Orthop Relat Res,2002,Apr (397):53-61.
  • 9BROOKS S,STARKIE C M,CLARKE N M.Osteosarcoma after the fourth decade.A clinico-pathological review[J].Arch Orthop Trauma Surg,1985,104 (2):100-105.
  • 10SONG W S,KONG C B,JEON D G,et al.Prognosis of extremity osteosarcoma in patients aged 40-60 years:A cohort/case controlled study at a single institute[J].Eur J Surg Oncol,2010,36 (5):483-488.

共引文献76

同被引文献23

  • 1孟祥龙,王庆一,曲铁兵,王进军,范广宇,王玉峰.凋亡基因bcl-xl在骨肉瘤中的表达[J].首都医科大学学报,2005,26(6):747-748. 被引量:1
  • 2Wu PK, Chen WM, Chen CF, et al. Primm7 osteogenie sarcoma with puhnonat7 metastasis : clinical results and prognostie factors in 91 patients[J]. Jpn J Clin 0ncol,2009,39(8) :514 -522.
  • 3Patane S,Avnet S, Cohella N, et al. MET overexpression turns hu- man primary osteoblasts into osteosarcomas [ J ]. Cancer Res,2006, 66 ( 9 ) :4750 - 4757.
  • 4Wong KC, Lee V, Shing MM, et al. Surgical resection of relapse may improve postrelapse survival of patients with localized osteosar- coma[ J]. Clin Orthop Relat Res,2013,471 (3) :814 -819.
  • 5Longhi A, Errani C, De Paolis M, et al. Primary bone osteosarcoma in the pediatric age : state of the art [ J ]. Cancer Treat Rev,2006,32 (6) :423 -436.
  • 6Jaffe N. Osteosareoma:review of the past,impact on the future. The American experience [ J ]. Cancer Treat Res, 2009,152 ( 1 ) : 239 - 262.
  • 7Baeei G,Roeca M,Salone M,et al. High grade osteosareoma of the extremities with lung metastases at presentation:Treatment with neoadjuvant chemotherapy and simultaneous resection of primary and metastatic lesions[J]. J Surg Oneol,2008,98(6) :415 -420.
  • 8Franek K J, Zhou Z, Zhang WD, et al. In vitro studies of baiealin a- lone or in combination with Salvia miltiorrhiza extract as a potentialanti - cancer agent [ J ]. Int J Oncol, 2005,26 ( 1 ) :217 - 224.
  • 9Cao R, Ji H, Yang, et al. Collaborative effects between the TNFct - TNFR1 - maerophage axis and the VEGF - C - VEGFR3 signa- ling in lymphangiogenesis and metastasis [ J ]. Oncoimmunology, 2015,4(3 ) :e989777.
  • 10Tang N, Song WX, Luo J, et al. Osteosarcoma development and stem cell differentiation [ J ]. Clin Orthop Relat Res, 2008,466 (9) :2114 -2130.

引证文献2

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部